Intact Vascular Announces Positive One-Year Data from the TOBA II Clinical Trial

First-of-its-kind study designed to demonstrate safety and efficacy of the Tack Endovascular System®in treating post-PTA dissections

WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced at the 15th annual VIVA conference in Las Vegas that its Tack Optimized Balloon Angioplasty II (TOBA II) clinical trial successfully achieved both primary and secondary endpoints. One year results from the TOBA II study were presented in the late-breaking scientific session by William Gray, M.D., System Chief, Division of Cardiovascular Disease at Main Line Health, President, Lankenau Heart Institute and Principal Investigator for the TOBA II trial.

Click here to read more.


©2018 PACT All Rights Reserved